Irvine, California | April 24, 2026

Johnson & Johnson has announced the launch of the PERSIGMA randomized controlled trial (RCT), marking a significant milestone in the evolution of pulsed field ablation (PFA) technologies for treating persistent atrial fibrillation (AFib). This landmark study is among the first to deliver head-to-head comparative data between two advanced PFA platforms, aiming to generate high-quality clinical evidence that can guide physician decision-making and improve patient outcomes in a rapidly advancing therapeutic area.

Head-to-Head Study to Strengthen Clinical Evidence

The PERSIGMA trial is designed to enroll up to 466 participants across 50 global clinical sites, where patients will be randomly assigned to receive treatment using either the VARIPULSE Pro Platform or the FARAPULSE PFA platform. The study focuses on evaluating both safety and effectiveness, with primary endpoints including freedom from arrhythmia recurrence within 60 days and the incidence of procedure-related adverse events.

This initiative reflects a growing demand within the electrophysiology community for direct comparative evidence between competing technologies, as current clinical decisions are often made without robust head-to-head data. By addressing this gap, the trial aims to raise the scientific rigor in evaluating PFA systems and establish clearer benchmarks for clinical performance.

The VARIPULSE Pro Platform, recently awarded CE mark in Europe, represents a next-generation innovation in ablation therapy, integrating enhanced pulse sequences and optimized irrigation systems to improve procedural efficiency and precision. Its compatibility with the CARTO mapping system further strengthens its role within a connected ecosystem of imaging, mapping, and therapy delivery, positioning it as a comprehensive solution in cardiac electrophysiology.

Advertisement

cGxPJobs Banner

Innovative Technology Driving AFib Treatment Evolution

Atrial fibrillation remains the most common sustained cardiac arrhythmia globally, posing a major public health challenge due to its progressive nature and association with stroke, heart failure, and increased mortality. As AFib advances from intermittent episodes to persistent forms, treatment becomes increasingly complex, requiring more precise and effective interventional strategies.

Pulsed field ablation (PFA) has emerged as a transformative technology in this space, offering a non-thermal mechanism that selectively targets cardiac tissue while minimizing damage to surrounding structures. However, not all PFA systems perform identically, underscoring the importance of comparative clinical trials like PERSIGMA.

Early data supporting the VARIPULSE platform, including findings from the VARIPURE study and real-world clinical evidence, suggest strong safety and performance outcomes. These advancements are further complemented by ongoing presentations at major scientific forums such as the Heart Rhythm Society (HRS) 2026 Congress, where early procedural insights from the PERSIGMA trial are being showcased.

Experts emphasize that such trials are critical for refining treatment strategies, procedural workflows, and patient selection criteria, ultimately enabling clinicians to deliver more personalized and effective care. The integration of advanced mapping systems and precision ablation tools also reflects the broader shift toward technology-driven cardiology solutions.

Future Impact on MedTech Innovation and Patient Outcomes

The launch of the PERSIGMA trial underscores Johnson & Johnson’s commitment to expanding its electrophysiology portfolio and strengthening the clinical evidence base for PFA technologies. By investing in rigorous, comparative research, the company aims to accelerate innovation while ensuring safety and efficacy standards remain paramount.

As healthcare systems increasingly prioritize evidence-based interventions, the outcomes of this trial could play a pivotal role in shaping future clinical guidelines and regulatory decisions for AFib treatment. The ability to directly compare technologies will empower physicians with actionable insights, enabling more confident adoption of advanced ablation techniques.

Moreover, the trial highlights a broader trend in the MedTech sector toward integrated, data-driven ecosystems that combine devices, software, and analytics to enhance procedural outcomes. Such innovations are expected to reduce complication rates, improve long-term rhythm control, and enhance patient quality of life.

With AFib affecting millions worldwide and its prevalence continuing to rise, the need for scalable, effective, and minimally invasive treatment options has never been greater. The PERSIGMA trial represents a crucial step forward in meeting this demand, reinforcing the role of cutting-edge medical technologies in addressing complex cardiovascular diseases.

Source: Johnson & Johnson press release